Results from trial of vemurafenib and cobimetinib and LDH as a predictive marker for outcome in BRAF-mutated melanoma

Results from trial of vemurafenib and cobimetinib and LDH as a predictive marker for outcome in BRAF-mutated melanoma

VJOncology

3 years
196 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Axel Hauschild, MD, PhD of University Hospital Schleswig-Holstein, Kiel, Germany, gives an overview of his talk on vemurafenib and cobimetinib for BRAF-mutated metastatic melanoma held at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. According to Prof. Hauschild, this trial (called coBRIM, NCT01689519) was similar to the trial on dabrafenib and trametinib (NCT01584648). The question was if the dual inhibition of crucial molecules of the signal transduction pathway is better than just knocking one of the molecules out. The answer is yes; the response rate was in the range of 70%, response duration was 13 months and the two year survival data is very promising (three year survival data is not available yet). Around 10-13% of patients had to discontinue treatment because of serious adverse events and some patients do not have any progressive disease after three years. For both clinical trials, he presented a subgroup analysis, which indicates that a simple serum marker like LDH (lactate dehydrogenase), is a good prognostic marker and a predictive marker for treatment outcome. The lower the LDH, the better the outcome for the patient. For patients with LDH that is elevated 2x or more, the prognosis is bad with low median overall survival (OS) and low chance for three year survival.
Up Next Autoplay
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Modeling Responses When Testing Less Frequently Than Monthly After Stopping Therapy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
Perspectives on the Future of CML
Perspectives on the Future of CML
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research  through study of von Hippel-Lindau (VHL) disease
2019 Nobel Prize for Medicine Recipients recognized for Cancer Research through study of von Hippel-Lindau (VHL) disease
Category: Acute Lymphoblastic Leukemia
1 Views
Cancer-News 13 hours
Re-evaluating TKI in CML Patients During Pregnancy
Re-evaluating TKI in CML Patients During Pregnancy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 13 hours
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Category: Acute Myelogenous Leukemia
2 Views
Cancer-News 13 hours
CML and Pregnancy
CML and Pregnancy
Category: Chronic Myelogenous Leukemia
1 Views
Cancer-News 14 hours
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
INNATE PHARMA HIGHLIGHTS FDA-APPROVED LUMOXITI® AT ASH 2019
Category: Acute Lymphoblastic Leukemia
3 Views
Cancer-News 14 hours
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refrac...
Category: Chronic Lymphocytic Leukemia
2 Views
Cancer-News 14 hours
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Category: Non-Hodgkin Lymphoma
4 Views
Cancer-News 14 hours
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
First Clinical Data with MGTA-145 Show Single-Day Dosing and Collection of Robust Numbers of High-Quality Stem Cells in Healthy Volunteers
Category: News
1 Views
Cancer-News 14 hours